JonesResearch has initiated coverage of ArriVent Biopharma (AVBP, Financial) with a positive outlook, assigning a Buy rating and a target price of $40. The firm highlights ArriVent's leading position in developing an oral EGFR TKI treatment for front-line atypical EGFR mutated non-small cell lung cancer. This treatment is designed as a monotherapy against EGFR exon 20 insertion and PACC mutations.
The firm anticipates significant developments in the coming years, with crucial Phase 3 clinical trial results for EGFR ex20ins mutated lung cancer expected in the latter half of 2025. Following these results, there is potential for FDA approval within 12 to 15 months. This strategic positioning and expected timeline contribute to the firm’s optimistic assessment of ArriVent Biopharma's prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for ArriVent BioPharma Inc (AVBP, Financial) is $39.43 with a high estimate of $45.00 and a low estimate of $36.00. The average target implies an upside of 103.77% from the current price of $19.35. More detailed estimate data can be found on the ArriVent BioPharma Inc (AVBP) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, ArriVent BioPharma Inc's (AVBP, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
